

ABX Pentra LDH IFCC CP

REF	A11A01871
REAGENT 1	26 mL
REAGENT 2	6.5 mL



IVD Rx Only

■ Pentra C200

HORIBA ABX SAS
Parc Euromédecine
Rue du Caducée
BP 7290
34184 Montpellier Cedex 4
FRANCE

Diagnostic reagent for quantitative *in vitro* determination of Lactate Dehydrogenase (LDH) in serum or plasma by colorimetry.

Application Release

Serum, plasma: LDHi

01.xx

Intended Use

ABX Pentra LDH IFCC CP reagent is intended for the quantitative *in vitro* diagnostic determination of Lactate Dehydrogenase (LDH) in serum or plasma.


Lactate dehydrogenase measurements are used in the diagnosis and treatment of liver diseases such as acute viral hepatitis, cirrhosis, and metastatic carcinoma of the liver, cardiac diseases such as myocardial infarction, and tumors of the lung or kidneys.

Clinical Interest (1, 2)

Lactate dehydrogenase (LDH) is an enzyme, consisting of five different isoenzymes that catalyze the interconversion of L-lactate and pyruvate. LDH is present in the cytoplasm of all human tissues with higher concentrations in liver, heart and skeletal muscle, and lower in erythrocytes, pancreas, kidney and stomach. Increased LDH activities are found in a variety of pathological conditions such as myocardial infarction, liver diseases, blood diseases, cancer or muscle diseases. However, because of the lack of organ specificity, determination of its isoenzymes or other enzymes such as alkaline phosphatase or ALAT / ASAT is necessary for differential diagnosis.

Method (3)

Optimized UV-test according to International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).



(LDH = Lactate Dehydrogenase)

Reagents ^a

ABX Pentra LDH IFCC CP is ready-to-use.

Reagent 1 (R1):

N-Methyl-D-Glucamine pH 9.40	420 mmol/L
L-Lactate	65 mmol/L

Reagent 2 (R2):

NAD ⁺	50 mmol/L
------------------	-----------

ABX Pentra LDH IFCC CP should be used according to this notice. The manufacturer cannot guarantee its performance if used otherwise.

Handling

1. Remove both caps of the cassette.
2. If present, remove foam by using a plastic pipette.
3. Place the cassette into the refrigerated Pentra C200 reagent compartment.

^aModification: § "Reagents": modification.

ABX Pentra LDH IFCC CP

Calibrator

For calibration, use:

ABX Pentra Multical (A11A01652) (not included)
10 x 3 mL (lyophilisate)

Control ^b

For internal quality control, use:

- **ABX Pentra N MultiControl** (1300054414) (not included)
10 x 5 mL (lyophilisate)
- **ABX Pentra P MultiControl** (1300054415) (not included)
10 x 5 mL (lyophilisate)

Each control should be assayed daily and/or after a calibration.

The frequency of controls and the confidence intervals should correspond to laboratory guidelines and country-specific directives. You should follow federal, state and local guidelines for testing quality control materials. The results must be within the range of the defined confidence limits. Each laboratory should establish a procedure to follow if the results exceed these confidence limits.

Materials Required but not Provided ^b

- Automated clinical chemistry analyzer: Pentra C200
- Calibrator: **ABX Pentra Multical** (A11A01652)
- Controls:
ABX Pentra N MultiControl (1300054414)
ABX Pentra P MultiControl (1300054415)
- Standard laboratory equipment.

Specimen ^{c d}

This device intended testing population is general population.

Specimen types

- Serum.
- Plasma in lithium heparin.

Anticoagulants other than those listed have not been tested by HORIBA Medical and are therefore not recommended for use with this assay.

Stability (1, 4)

- At 20-25°C: 7 days
- At 2-8°C: 4 days
- At -20°C: 6 weeks

For routine analysis, the serum should be stored at room temperature because of the sensitivity of LD-4 and LD-5 to cold conditions.

Reference Range (5) ^e

Each laboratory should establish its own reference ranges. The values given here are used as guidelines only.

37°C

Women: < 247 [U/L]
Men: < 248 [U/L]

Clinical sensitivity and specificity, positive predictive value and negative predictive value are not commonly reported for this analyte. This is largely attributed to the fact that this analyte is not sole indicator for the intended purpose and patient treatment decision making. To arrive at a diagnosis and a course of treatment, results from others routine clinical chemistry tests should be used in conjunction with other diagnostic information and the attending health-care professional's evaluation of the patient's condition.

Storage and Stability

Stability before opening:

Stable up to the expiry date on the label if stored at 2-8°C. Store protected from light.

Stability after opening:

Refer to the paragraph "Performance on Pentra C200".

Do not freeze.

^bModification: control removed.

^cModification: modification of "Specimen".

^dModification: modification of specimen stability.

^eModification: information added.

ABX Pentra LDH IFCC CP

Waste Management

Please refer to local legal requirements.

General Precautions ^f

- This reagent is for professional *in vitro* diagnostic use only.
For laboratory use.
- For prescription use only.
- This reagent is classified as non-hazardous in compliance with regulation (EC) N°.1272/2008.
- Do not pipette by mouth.
- Do not replenish the reagents.
- Do not swallow. Avoid contact with skin and mucous membranes.
- Observe the standard laboratory precautions for use.
- The reagent cassettes are disposable and should be disposed of in accordance with the local legal requirements.
- Please refer to the SDS associated with the reagent.
- Do not use the product if there is visible evidence of biological, chemical or physical deterioration.
- Do not use the product if the recommended storage conditions, including temperature, are not followed.
- User must be trained by a HORIBA Medical representative before attempting to operate the device.
- It is the user's responsibility to verify that this document is applicable to the reagent used.
- For technical assistance, you can call +33 (0)4 67 14 15 16.
- Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the country in which the user and/or the patient is established.

Performance on Pentra C200

Lot to Lot Variability ^g

The recovery of samples (serum and plasma) done during QC release of three consecutive lots of reagent shows that the lot to lot variability is within specification: < 10%.

Serum, plasma

The performance data listed below have been obtained on the Pentra C200 analyzer.

Number of tests: approximately 121 tests

On Board Reagent Stability

Once opened, the reagent cassette placed in the refrigerated Pentra C200 compartment is stable for 30 days.

Sample volume: 7 µL/test

Detection Limit ^h

The detection limit is determined according to CLSI (NCCLS), EP17-A2 protocol (6) and equals 5.10 U/L.

Limit of Quantitation ⁱ

The limit of quantitation is determined according to CLSI (NCCLS), EP17-A2 protocol (6) and equals 20 U/L.

Accuracy and Precision

Repeatability (*within-run precision*)

Repeatability according to the recommendations found in the Valtec protocol (7) with samples tested 20 times:

- 2 controls
- 3 specimens (low / medium / high levels)

	Mean value U/L	CV %
Control specimen 1	157	1.21
Control specimen 2	264	1.37
Specimen 1	78	2.08
Specimen 2	154	1.10
Specimen 3	433	0.76

Reproducibility (*total precision*)

Reproducibility according to the recommendations found in the CLSI (NCCLS), EP5-A2 protocol (8) with samples tested in duplicate for 20 days (2 series per day):

- 2 controls
- 3 specimens (low / medium / high levels)

	Mean value U/L	CV %
Control specimen 1	156.02	5.7
Control specimen 2	260.26	4.3
Specimen 1	76.73	5.6

^fModification: general precautions modification.

^gModification: chapter added.

^hModification: data added.

ⁱModification: modification of quantitation limit.

ABX Pentra LDH IFCC CP

	Mean value U/L	CV %
Specimen 2	153.77	5.3
Specimen 3	460.15	3.7

Measuring Range ^j

The assay confirmed a measuring range from 20 U/L to 800 U/L.

The measuring range is extended up to 2400 U/L with the automatic post-dilution.

The reagent linearity has been assessed up to 800 U/L according to the recommendations found in the CLSI (NCCLS), EP06-Ed2 protocol (9).

Correlation ^k

Patient samples: Serum

Number of patient samples: 112

Specimens are correlated with a commercial reagent taken as reference according to the recommendations found in the CLSI (NCCLS), EP09c protocol (10).

Values ranged from 45.0 U/L to 791.0 U/L.

The equation for the allometric line obtained using Passing-Bablok regression procedure (11) is:

$$Y = 1.06 X - 10.63 \text{ (U/L)}$$

with a correlation coefficient $r^2 = 0.993$.

Interferences ^l

Haemoglobin: Do not use hemolysed samples.

Triglycerides: No significant influence is observed up to a triglyceride concentration of 6.33 mmol/L (553.88 mg/dL).

Total Bilirubin: No significant influence is observed up to 500 µmol/L (29.3 mg/dL).

Direct Bilirubin: No significant influence is observed up to 787.5 µmol/L (46.1 mg/dL).

Sulfasalazine: No significant influence is observed up to 754 µmol/L (30.01 mg/dL).

Sulfapyridine: No significant influence is observed up to 1.2 mmol/L (29.88 mg/dL).

Other limitations are given by Young as a list of drugs and preanalytical variables known to affect this methodology (12, 13).

Calibration Stability

The reagent is calibrated on Day 0. The calibration stability is checked by testing 2 control specimens.

The calibration stability is 7 days.

Note: A recalibration is recommended when reagent lots change, and when quality control results fall outside the range established.

Reference

1. Thomas L. Clinical laboratory diagnostics. 1st ed. Frankfurt: THBooks Verlagsgesellschaft (1998): 89-94.
2. Moss DW, Henderson AR. Clinical enzymology In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders Company (1999): 617-721.
3. Deutsche Gesellschaft für Klinische Chemie. Empfehlungen der deutschen Gesellschaft für Klinische Chemie (DGCK). Standardisierung von Methoden zur Bestimmung von Enzymaktivitäten in biologischen Flüssigkeiten. (Recommendation of the German Society of Clinical Chemistry. Standardization of methods for measurement of enzymatic activities in biological fluids.) Z. Klin. Chem. Klin. Biochem. (1972) **10**: 182-192.
4. Use of anticoagulants in diagnostic laboratory investigations. WHO publication WHO/DIL/LAB/99.1 Rev. 2 (2002): 36.
5. Schumann G, Bonora R, Ceriotti F, Féraud G et al. IFCC primary reference procedure for the measurement of catalytic activity concentrations of enzymes at 37°C. Part 3: Reference procedure for the measurement of catalytic concentration of lactate dehydrogenase. Clin. Chem. Lab. Med. (2002) **40**: 643-648.
6. Evaluation of detection capability for clinical laboratory measurement procedures. Approved Guideline, 2nd ed., CLSI (NCCLS) document EP17-A2 (2012) **32** (8).
7. Vassault A, Grafmeyer D, Naudin C et al. Protocoles de validation de techniques (document B). Ann. Biol. Clin. (1986) **44**: 686-745.
8. Evaluation of Precision Performance of Quantitative Measurement Method. Approved Guideline, CLSI (NCCLS) document EP5-A2 (2004) **24** (25).
9. Evaluation of Linearity of Quantitative Measurement Procedures. 2nd Edition, CLSI (NCCLS) guideline EP06-Ed2 (2020) **40** (16).
10. Measurement Procedure Comparison and Bias Estimation Using Patient Samples. Approved Guideline, 3rd ed., CLSI (NCCLS) document EP09c (2018) **38** (12).
11. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J. Clin. Chem. Clin. Biochem. (1983) **21**: 709-720.

^jModification: modification of measuring range.

^kModification: modification of correlation.

^lModification: modification of interferences.

ABX Pentra LDH IFCC CP

12. Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th Edition, Washington, DC, AACC Press (2000).
13. Young DS. Effects of Preanalytical Variables on Clinical Laboratory Tests. 2nd Edition, Washington, DC, AACC Press (1997) **3**: 120-132.

